Measurement of specific cellular immune responses in patients undergoing im
munotherapy is difficult. Established approaches, including cytotoxicity (e
.g., Cr-51 release) and cytokine release assays, require in vitro culturing
for several weeks or more of patients' peripheral blood mononuclear cells
(PBMC) and the addition of exogenous cytokines. Therefore, the immunologica
l response does not reflect in vivo conditions. To address these disadvanta
ges, we have used an interferon-gamma (IFN-gamma) Elispot assay for detecti
ng peptide-specific CD8(+) lymphocytes in PBMC. A limitation of this assay
is the lack of a reproducible source of antigen-presenting cells (APCs). Cu
rrently available APCs often lead to significant background levels. It has
been shown that transfected insect cells can express empty MHC class I mole
cules on their surface. We have transfected Drosophila melanogaster S2 cell
s and the Lepidopteran line Sf9 with the gene encoding human HLA-A2.1. We d
emonstrate that insect cells expressing a human HLA molecule effectively fu
nction as APCs in the IFN-gamma Elispot assay. Initially the feasibility of
the assay was assessed using CD8(+) T cells from HLA-A2.1(+) donors with k
nown reactivity against an HLA-A2.1-binding epitope of the influenza matrix
protein. Use of insect cells as APCs abrogated background spots, increasin
g sensitivity. We further observed that a short-term prestimulation of PBMC
with peptide-pulsed insect cells markedly enhanced the frequency of peptid
e-specific T cells that could be measured in the Elispot assay without incr
easing the background. This approach was then used to measure CD8(+) T cell
reactivity to a peptide from tyrosinase, an antigen that is processed and
presented by melanoma cells. Insect cells expressing human HLA molecules pr
ovide a standard APC for monitoring CD8(+) T cell responses to tumor and vi
ral peptides during immunotherapy. (C) 2000 Elsevier Science B.V. All right
s reserved.